Clinical Trials Logo

Clinical Trial Summary

The goal of this intervention study is to test a behavioral intervention to increase inclusionary practices toward individuals with serious mental illness in faith communities. The main questions it aims to answer are: 1. To determine if the behavior-based intervention leads to an increase in inclusionary practices (e.g., conducting outreach with mental health agencies). 2. To determine if the behavior-based intervention is effective in increasing inclusive practices by members and leaders of faith communities. 3. To determine if the intervention leads to a greater understand of mental illness and a decrease in stigmatizing beliefs by congregation members. 4. To determine if the intervention results in individuals with serious mental illness and their family members reporting less discrimination and increased inclusion. Congregations will be asked to create an inclusion committee that will then work on developing systems and changing congregational practices to become more inclusive. All congregation members will be invited to a half-day training that will provide information on mental illness and inclusion, and will provide tips and strategies when they encounter situations or behaviors that are less familiar to them. All congregation members will be given the opportunity to participate in a survey about congregational practices.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06336980
Study type Interventional
Source Temple University
Contact Crystal Slanzi, PhD
Email crystal.slanzi@temple.edu
Status Recruiting
Phase N/A
Start date January 22, 2024
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT03489187 - Visualase Visualization Database (VIVID-1)
Completed NCT06312449 - Effect of Peanut Balls Used of the Second Stage of Labor, Pushing Perceptions, Fatigue and Birth Outcomes N/A
Completed NCT03775694 - Diffusion MRI-1 Imaging Database
Recruiting NCT00840047 - Methionine PET/CT Studies In Patients With Cancer Phase 2
Completed NCT04236921 - Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis) Phase 1
Terminated NCT04240158 - IW-6463 Safety Study in Healthy Elderly Subjects Phase 1
Completed NCT03856827 - A Study of IW-6463 in Healthy Volunteers Phase 1
No longer available NCT03723083 - Expanded Access for CC-2001